Home › Funds › ACUTA CAPITAL PARTNERS, LLC › FDMT
ACUTA CAPITAL PARTNERS, LLC position in FDMT
4D MOLECULAR THERAPEUTICS IN · Health Care
ACUTA CAPITAL PARTNERS, LLC reported holding 535,109 shares of FDMT (4D MOLECULAR THERAPEUTICS IN) in its Q3 2026 13F filing — a position valued at US$7.7M, representing 6.04% of its reported portfolio and ranking #4 among its reported holdings. ACUTA CAPITAL PARTNERS, LLC has disclosed FDMT holdings in 4 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How ACUTA CAPITAL PARTNERS, LLC's FDMT position evolved
ACUTA CAPITAL PARTNERS, LLC first disclosed a stake in FDMT in Q4 2023 at 74,500 shares (US$1.5M). The position peaked in Q3 2026 at 535,109 shares, worth US$7.7M. Across 4 filings, ACUTA CAPITAL PARTNERS, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 535,109 shares valued at US$7.7M — an increase of 27,308 shares quarter over quarter.. Notable position changes include a 110% increase in Q2 2026 (shares rose 8% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 74.50K | $1.51M | New |
| Q1 2026 | 242.25K | $2.26M | New |
| Q2 2026 | 507.80K | $6.75M | Add |
| Q3 2026 | 535.11K | $7.66M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About FDMT and 13F data
FDMT (4D MOLECULAR THERAPEUTICS IN) is a Health Care company. 34 other funds we track also report a position in FDMT — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$67.2M), Novo Holdings A/S (US$43.2M), BVF INC/IL (US$38.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding FDMT
- RA CAPITAL MANAGEMENT, L.P. 5.05M sh · $67.16M · Q2 2026
- Novo Holdings A/S 3.25M sh · $43.21M · Q2 2026
- BVF INC/IL 2.88M sh · $38.29M · Q2 2026
- Trails Edge Capital Partners, LP 2.23M sh · $31.88M · Q3 2026
- ARMISTICE CAPITAL, LLC 1.95M sh · $27.90M · Q3 2026
- Evergreen Quality Fund GP, Ltd. 951.47K sh · $12.65M · Q2 2026
- Parkman Healthcare Partners LLC 772.18K sh · $11.05M · Q3 2026
- Catalio Capital Management, LP 471.25K sh · $6.27M · Q2 2026
- DIADEMA PARTNERS LP 421.11K sh · $6.03M · Q3 2026
- Opaleye Management Inc. 334.44K sh · $4.45M · Q2 2026
More on ACUTA CAPITAL PARTNERS, LLC
FAQ
How long has ACUTA CAPITAL PARTNERS, LLC held FDMT?
ACUTA CAPITAL PARTNERS, LLC has disclosed FDMT holdings in 4 of the last 12 reported quarters, going back to Q4 2023.
What is ACUTA CAPITAL PARTNERS, LLC's current position in FDMT?
As of Q3 2026, ACUTA CAPITAL PARTNERS, LLC holds 535.11K shares of FDMT (4D MOLECULAR THERAPEUTICS IN), valued at $7.66M, representing 6.04% of its reported portfolio and ranking #4.
Has ACUTA CAPITAL PARTNERS, LLC been buying or selling FDMT?
In the latest 13F filing (Q3 2026), ACUTA CAPITAL PARTNERS, LLC increased its position in FDMT. The position peaked in Q3 2026 at 535.11K shares.
Which other funds hold FDMT?
Other major institutional holders of FDMT include RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, BVF INC/IL, among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.